HilleVax, Inc. (NASDAQ:HLVX) Director Sells $10,230.45 in Stock

HilleVax, Inc. (NASDAQ:HLVX) Director Aditya Kohli sold 723 shares of HilleVax stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $14.15, for a total transaction of $10,230.45. Following the transaction, the director now directly owns 782,878 shares of the company’s stock, valued at $11,077,723.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Aditya Kohli also recently made the following trade(s):

• On Wednesday, May 1st, Aditya Kohli sold 175 shares of HilleVax stock. The stock was sold at an average price of $14.03, for a total transaction of $2,455.25.
• On Friday, April 5th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $14.44, for a total value of $86,640.00.
• On Wednesday, April 3rd, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $14.93, for a total value of $89,580.00.
• On Wednesday, March 20th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $164,221.00, for a total value of $985,326,000.00.
• On Monday, March 18th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $17.66, for a total value of $105,960.00.
• On Friday, March 8th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $18.66, for a total value of $111,960.00.
• On Wednesday, March 6th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $18.95, for a total transaction of $113,700.00.
• On Thursday, February 22nd, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $15.05, for a total transaction of $90,300.00.
• On Tuesday, February 20th, Aditya Kohli sold 6,000 shares of HilleVax stock. The shares were sold at an average price of $14.88, for a total transaction of $89,280.00.
• On Monday, February 12th, Aditya Kohli sold 6,000 shares of HilleVax stock. The stock was sold at an average price of $15.32, for a total transaction of $91,920.00.

HilleVax Stock Down 2.9 %

Shares of NASDAQ HLVX opened at $13.61 on Monday. The firm’s 50-day moving average is $15.62 and its 200-day moving average is $14.70. The firm has a market capitalization of $676.69 million, a PE ratio of -4.48 and a beta of 0.79. The company has a current ratio of 10.62, a quick ratio of 10.62 and a debt-to-equity ratio of 0.10. HilleVax, Inc. has a 1 year low of $9.94 and a 1 year high of $20.22.

HilleVax (NASDAQ:HLVX) last released its quarterly earnings results on Wednesday, March 20th. The company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.02. Equities analysts expect that HilleVax, Inc. will post -3.22 EPS for the current year.

Hedge Funds Weigh In On HilleVax

Several institutional investors and hedge funds have recently added to or reduced their stakes in HLVX. Catalys Pacific LLC bought a new stake in HilleVax in the fourth quarter valued at approximately $21,009,000. Deerfield Management Company L.P. Series C boosted its stake in shares of HilleVax by 20.3% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 4,004,231 shares of the company’s stock valued at $53,857,000 after purchasing an additional 675,000 shares during the last quarter. Acuta Capital Partners LLC increased its position in shares of HilleVax by 328.5% during the third quarter. Acuta Capital Partners LLC now owns 270,319 shares of the company’s stock worth $3,636,000 after buying an additional 207,241 shares during the period. Braidwell LP raised its stake in HilleVax by 16.0% during the third quarter. Braidwell LP now owns 1,449,246 shares of the company’s stock worth $19,492,000 after buying an additional 200,000 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new position in HilleVax in the third quarter valued at $2,374,000. 86.42% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $28.00 price objective on shares of HilleVax in a research report on Thursday, March 21st.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.